{"id":93125,"date":"2026-08-19T14:11:07","date_gmt":"2026-08-19T18:11:07","guid":{"rendered":"https:\/\/livingstonepartners.com\/?post_type=transaction&#038;p=93125"},"modified":"2026-08-19T14:11:07","modified_gmt":"2026-08-19T18:11:07","slug":"livingstone-advises-neoplas-meds-series-b-financing-round","status":"publish","type":"transaction","link":"https:\/\/livingstonepartners.com\/fr\/transaction\/livingstone-advises-neoplas-meds-series-b-financing-round\/","title":{"rendered":"Livingstone conseille neoplas med dans le cadre de sa lev\u00e9e de fonds de s\u00e9rie B"},"content":{"rendered":"\n<p><strong>L&rsquo;\u00e9quipe Sant\u00e9 de Livingstone \u00e0 D\u00fcsseldorf a poursuivi son r\u00f4le de conseil aupr\u00e8s de <\/strong><a target=\"_blank\" rel=\"noopener noreferrer\" href=\"https:\/\/neoplas-med.eu\/en\/\"><strong>neoplas med GmbH<\/strong><\/a><strong> pour son second tour de table. <\/strong><a target=\"_blank\" rel=\"noopener noreferrer\" href=\"https:\/\/niterra.de\/\"><strong>Niterra<\/strong><\/a><strong> (anciennement NGK Spark Plug Co., LTD) renforce son partenariat avec la soci\u00e9t\u00e9 medtech \u00e0 travers un investissement de croissance en partenariat avec <\/strong><a target=\"_blank\" rel=\"noopener noreferrer\" href=\"https:\/\/www.pegasustechventures.com\/\"><strong>Pegasus Technology Ventures<\/strong><\/a><strong>. Cet investissement vise \u00e0 soutenir le d\u00e9veloppement international de neoplas med, bas\u00e9e \u00e0 Greifswald en Allemagne, et \u00e0 acc\u00e9l\u00e9rer la mise au point de nouveaux produits et applications de sa technologie de plasma froid.<\/strong><\/p><p>En juin 2022, Livingstone avait conseill\u00e9 neoplas med GmbH lors de son premier tour de table, permettant d&rsquo;attirer le groupe technologique japonais NGK Spark Plug (exer\u00e7ant sous le nom de Niterra depuis avril 2023) en tant que partenaire strat\u00e9gique. neoplas med a d\u00e9velopp\u00e9 une th\u00e9rapie pour le traitement des plaies chroniques et infect\u00e9es, au cours de laquelle le plasma froid est appliqu\u00e9 sans contact, sous contr\u00f4le visuel et de mani\u00e8re quasiment indolore. Le plasma froid \u00e9mis par le <a target=\"_blank\" rel=\"noopener noreferrer\" href=\"https:\/\/neoplas-med.eu\/en\/product\/\">kINPen\u00ae MED<\/a> \u00e9limine les germes et agents pathog\u00e8nes et stimule la microcirculation, ainsi que la n\u00e9ovascularisation et la prolif\u00e9ration cellulaire.<\/p><p>Niterra est un groupe technologique japonais sp\u00e9cialis\u00e9 depuis sa cr\u00e9ation dans les bougies d&rsquo;allumage, la technologie des capteurs et la c\u00e9ramique technique. Sa division m\u00e9dicale d\u00e9veloppe des technologies dans les domaines de la sant\u00e9 respiratoire, de la sant\u00e9 f\u00e9minine, des soins \u00e0 domicile et du plasma froid. Affichant un bilan de plus d&rsquo;un milliard de dollars et s&rsquo;appuyant sur un fonds de Corporate Venture Capital de 100 millions de dollars cr\u00e9\u00e9 en partenariat avec Pegasus Tech Ventures, Niterra investit \u00e0 l&rsquo;\u00e9chelle mondiale dans des technologies de pointe, notamment les dispositifs m\u00e9dicaux.<\/p><p><em>\u00ab Nous avons doubl\u00e9 notre chiffre d&rsquo;affaires en 2022 et nous remercions notre partenaire strat\u00e9gique Niterra pour sa confiance et son soutien dans la poursuite de notre d\u00e9veloppement international et le d\u00e9ploiement de nouveaux canaux de distribution. Nous sommes fiers de ce r\u00e9sultat solide et ravis que Niterra renforce son engagement strat\u00e9gique \u00e0 nos c\u00f4t\u00e9s. Il s&rsquo;agit d&rsquo;une nouvelle \u00e9tape majeure dans nos efforts pour faire \u00e9voluer notre technologie novatrice de jet de plasma et la rendre accessible au plus grand nombre \u00e0 travers le monde \u00bb, <\/em>d\u00e9clare <strong>Ulrike Sailer, CEO de neoplas med GmbH<\/strong>.<\/p><p><em>&nbsp;\u00ab La technologie de neoplas med et sa reconnaissance au sein de la communaut\u00e9 m\u00e9dicale nous ont s\u00e9duits d\u00e8s le premier jour. Sous la direction d&rsquo;Ulrike Sailer, la soci\u00e9t\u00e9 s&rsquo;est tr\u00e8s bien d\u00e9velopp\u00e9e et je suis particuli\u00e8rement enthousiaste quant \u00e0 son potentiel de croissance future \u00bb, <\/i>souligne <strong>Dirk<\/strong> <strong>Schapeler<\/strong>,<strong> pr\u00e9sident de Niterra Ventures Company<\/strong><em>.<\/em><\/p><p><a rel=\"noopener noreferrer\" href=\"https:\/\/livingstonepartners.com\/fr\/team\/dr-ralf-nowak\/\"><strong>Dr. Ralf Nowak<\/strong><\/a><strong>,<\/strong> <strong>Associ\u00e9 chez Livingstone \u00e0 D\u00fcsseldorf<\/strong>, commente : <em>\u00ab Nous sommes tr\u00e8s heureux d&rsquo;accompagner neoplas med dans sa transition d&rsquo;une start-up vers une entreprise technologique dynamique. Niterra est un partenaire id\u00e9al pour neoplas med, soutenant son expansion internationale continue ainsi que la diversification de sa gamme de produits et de ses domaines d&rsquo;application. \u00bb<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"<p>neoplas med et Niterra renforcent leur partenariat strat\u00e9gique<\/p>\n","protected":false},"featured_media":97071,"template":"","meta":{"_acf_changed":false,"footnotes":"","_links_to":"","_links_to_target":""},"client-type":[],"region":[],"sector":[],"service":[],"transaction-type":[],"class_list":["post-93125","transaction","type-transaction","status-publish","has-post-thumbnail","hentry"],"acf":{"team_members":[93327,93353],"date":"20230424","client_type":3158,"type":[3266],"region":[3175,3182,3174],"services":[],"sectors":[3287,3291],"related_transactions":[93117,93040,92975,92933],"related_testimonials":"","contacts":""},"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v28.5 (Yoast SEO v28.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Livingstone conseille neoplas med dans le cadre de sa lev\u00e9e de fonds de s\u00e9rie B - Livingstone Partners<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/livingstonepartners.com\/fr\/transaction\/livingstone-advises-neoplas-meds-series-b-financing-round\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Livingstone conseille neoplas med dans le cadre de sa lev\u00e9e de fonds de s\u00e9rie B\" \/>\n<meta property=\"og:description\" content=\"neoplas med et Niterra renforcent leur partenariat strat\u00e9gique\" \/>\n<meta property=\"og:url\" content=\"https:\/\/livingstonepartners.com\/fr\/transaction\/livingstone-advises-neoplas-meds-series-b-financing-round\/\" \/>\n<meta property=\"og:site_name\" content=\"Livingstone Partners\" \/>\n<meta property=\"og:image\" content=\"https:\/\/livingstonepartners.com\/wp-content\/uploads\/2026\/05\/18343c2a.png\" \/>\n\t<meta property=\"og:image:width\" content=\"550\" \/>\n\t<meta property=\"og:image:height\" content=\"370\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/livingstonepartners.com\\\/fr\\\/transaction\\\/livingstone-advises-neoplas-meds-series-b-financing-round\\\/\",\"url\":\"https:\\\/\\\/livingstonepartners.com\\\/fr\\\/transaction\\\/livingstone-advises-neoplas-meds-series-b-financing-round\\\/\",\"name\":\"Livingstone conseille neoplas med dans le cadre de sa lev\u00e9e de fonds de s\u00e9rie B - Livingstone Partners\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/livingstonepartners.com\\\/fr\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/livingstonepartners.com\\\/fr\\\/transaction\\\/livingstone-advises-neoplas-meds-series-b-financing-round\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/livingstonepartners.com\\\/fr\\\/transaction\\\/livingstone-advises-neoplas-meds-series-b-financing-round\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/livingstonepartners.com\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/18343c2a.png\",\"datePublished\":\"2026-08-19T18:11:07+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/livingstonepartners.com\\\/fr\\\/transaction\\\/livingstone-advises-neoplas-meds-series-b-financing-round\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/livingstonepartners.com\\\/fr\\\/transaction\\\/livingstone-advises-neoplas-meds-series-b-financing-round\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/livingstonepartners.com\\\/fr\\\/transaction\\\/livingstone-advises-neoplas-meds-series-b-financing-round\\\/#primaryimage\",\"url\":\"https:\\\/\\\/livingstonepartners.com\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/18343c2a.png\",\"contentUrl\":\"https:\\\/\\\/livingstonepartners.com\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/18343c2a.png\",\"width\":550,\"height\":370},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/livingstonepartners.com\\\/fr\\\/transaction\\\/livingstone-advises-neoplas-meds-series-b-financing-round\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Homepage\",\"item\":\"https:\\\/\\\/livingstonepartners.com\\\/fr\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Transactions\",\"item\":\"https:\\\/\\\/livingstonepartners.com\\\/fr\\\/transaction\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Livingstone advises neoplas med\u2019s series B financing round\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/livingstonepartners.com\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/livingstonepartners.com\\\/fr\\\/\",\"name\":\"Livingstone Partners\",\"description\":\"Deals Done Right.\",\"publisher\":{\"@id\":\"https:\\\/\\\/livingstonepartners.com\\\/fr\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/livingstonepartners.com\\\/fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/livingstonepartners.com\\\/fr\\\/#organization\",\"name\":\"Livingstone Partners\",\"url\":\"https:\\\/\\\/livingstonepartners.com\\\/fr\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/livingstonepartners.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/livingstonepartners.com\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/logo_livingstone.svg\",\"contentUrl\":\"https:\\\/\\\/livingstonepartners.com\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/logo_livingstone.svg\",\"caption\":\"Livingstone Partners\"},\"image\":{\"@id\":\"https:\\\/\\\/livingstonepartners.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.linkedin.com\\\/company\\\/livingstone\\\/\"],\"description\":\"Livingstone is an independent, global M&A and debt advisory firm with a proven track record of delivering exceptional outcomes for private and public businesses and private equity investors.\",\"email\":\"marketing@livingstonepartners.com\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Livingstone conseille neoplas med dans le cadre de sa lev\u00e9e de fonds de s\u00e9rie B - Livingstone Partners","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/livingstonepartners.com\/fr\/transaction\/livingstone-advises-neoplas-meds-series-b-financing-round\/","og_locale":"fr_FR","og_type":"article","og_title":"Livingstone conseille neoplas med dans le cadre de sa lev\u00e9e de fonds de s\u00e9rie B","og_description":"neoplas med et Niterra renforcent leur partenariat strat\u00e9gique","og_url":"https:\/\/livingstonepartners.com\/fr\/transaction\/livingstone-advises-neoplas-meds-series-b-financing-round\/","og_site_name":"Livingstone Partners","og_image":[{"width":550,"height":370,"url":"https:\/\/livingstonepartners.com\/wp-content\/uploads\/2026\/05\/18343c2a.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/livingstonepartners.com\/fr\/transaction\/livingstone-advises-neoplas-meds-series-b-financing-round\/","url":"https:\/\/livingstonepartners.com\/fr\/transaction\/livingstone-advises-neoplas-meds-series-b-financing-round\/","name":"Livingstone conseille neoplas med dans le cadre de sa lev\u00e9e de fonds de s\u00e9rie B - Livingstone Partners","isPartOf":{"@id":"https:\/\/livingstonepartners.com\/fr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/livingstonepartners.com\/fr\/transaction\/livingstone-advises-neoplas-meds-series-b-financing-round\/#primaryimage"},"image":{"@id":"https:\/\/livingstonepartners.com\/fr\/transaction\/livingstone-advises-neoplas-meds-series-b-financing-round\/#primaryimage"},"thumbnailUrl":"https:\/\/livingstonepartners.com\/wp-content\/uploads\/2026\/05\/18343c2a.png","datePublished":"2026-08-19T18:11:07+00:00","breadcrumb":{"@id":"https:\/\/livingstonepartners.com\/fr\/transaction\/livingstone-advises-neoplas-meds-series-b-financing-round\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/livingstonepartners.com\/fr\/transaction\/livingstone-advises-neoplas-meds-series-b-financing-round\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/livingstonepartners.com\/fr\/transaction\/livingstone-advises-neoplas-meds-series-b-financing-round\/#primaryimage","url":"https:\/\/livingstonepartners.com\/wp-content\/uploads\/2026\/05\/18343c2a.png","contentUrl":"https:\/\/livingstonepartners.com\/wp-content\/uploads\/2026\/05\/18343c2a.png","width":550,"height":370},{"@type":"BreadcrumbList","@id":"https:\/\/livingstonepartners.com\/fr\/transaction\/livingstone-advises-neoplas-meds-series-b-financing-round\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Homepage","item":"https:\/\/livingstonepartners.com\/fr\/"},{"@type":"ListItem","position":2,"name":"Transactions","item":"https:\/\/livingstonepartners.com\/fr\/transaction\/"},{"@type":"ListItem","position":3,"name":"Livingstone advises neoplas med\u2019s series B financing round"}]},{"@type":"WebSite","@id":"https:\/\/livingstonepartners.com\/fr\/#website","url":"https:\/\/livingstonepartners.com\/fr\/","name":"Livingstone Partners","description":"Deals Done Right.","publisher":{"@id":"https:\/\/livingstonepartners.com\/fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/livingstonepartners.com\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/livingstonepartners.com\/fr\/#organization","name":"Livingstone Partners","url":"https:\/\/livingstonepartners.com\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/livingstonepartners.com\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/livingstonepartners.com\/wp-content\/uploads\/2026\/05\/logo_livingstone.svg","contentUrl":"https:\/\/livingstonepartners.com\/wp-content\/uploads\/2026\/05\/logo_livingstone.svg","caption":"Livingstone Partners"},"image":{"@id":"https:\/\/livingstonepartners.com\/fr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.linkedin.com\/company\/livingstone\/"],"description":"Livingstone is an independent, global M&A and debt advisory firm with a proven track record of delivering exceptional outcomes for private and public businesses and private equity investors.","email":"marketing@livingstonepartners.com"}]}},"_links":{"self":[{"href":"https:\/\/livingstonepartners.com\/fr\/wp-json\/wp\/v2\/transaction\/93125","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/livingstonepartners.com\/fr\/wp-json\/wp\/v2\/transaction"}],"about":[{"href":"https:\/\/livingstonepartners.com\/fr\/wp-json\/wp\/v2\/types\/transaction"}],"version-history":[{"count":0,"href":"https:\/\/livingstonepartners.com\/fr\/wp-json\/wp\/v2\/transaction\/93125\/revisions"}],"acf:post":[{"embeddable":true,"href":"https:\/\/livingstonepartners.com\/fr\/wp-json\/wp\/v2\/transaction\/92933"},{"embeddable":true,"href":"https:\/\/livingstonepartners.com\/fr\/wp-json\/wp\/v2\/transaction\/92975"},{"embeddable":true,"href":"https:\/\/livingstonepartners.com\/fr\/wp-json\/wp\/v2\/transaction\/93040"},{"embeddable":true,"href":"https:\/\/livingstonepartners.com\/fr\/wp-json\/wp\/v2\/transaction\/93117"},{"embeddable":true,"href":"https:\/\/livingstonepartners.com\/fr\/wp-json\/wp\/v2\/team-member\/93353"},{"embeddable":true,"href":"https:\/\/livingstonepartners.com\/fr\/wp-json\/wp\/v2\/team-member\/93327"}],"acf:term":[{"embeddable":true,"taxonomy":"sector","href":"https:\/\/livingstonepartners.com\/fr\/wp-json\/wp\/v2\/sector\/3291"},{"embeddable":true,"taxonomy":"sector","href":"https:\/\/livingstonepartners.com\/fr\/wp-json\/wp\/v2\/sector\/3287"},{"embeddable":true,"taxonomy":"region","href":"https:\/\/livingstonepartners.com\/fr\/wp-json\/wp\/v2\/region\/3174"},{"embeddable":true,"taxonomy":"region","href":"https:\/\/livingstonepartners.com\/fr\/wp-json\/wp\/v2\/region\/3182"},{"embeddable":true,"taxonomy":"region","href":"https:\/\/livingstonepartners.com\/fr\/wp-json\/wp\/v2\/region\/3175"},{"embeddable":true,"taxonomy":"transaction-type","href":"https:\/\/livingstonepartners.com\/fr\/wp-json\/wp\/v2\/transaction-type\/3266"},{"embeddable":true,"taxonomy":"client-type","href":"https:\/\/livingstonepartners.com\/fr\/wp-json\/wp\/v2\/client-type\/3158"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/livingstonepartners.com\/fr\/wp-json\/wp\/v2\/media\/97071"}],"wp:attachment":[{"href":"https:\/\/livingstonepartners.com\/fr\/wp-json\/wp\/v2\/media?parent=93125"}],"wp:term":[{"taxonomy":"client-type","embeddable":true,"href":"https:\/\/livingstonepartners.com\/fr\/wp-json\/wp\/v2\/client-type?post=93125"},{"taxonomy":"region","embeddable":true,"href":"https:\/\/livingstonepartners.com\/fr\/wp-json\/wp\/v2\/region?post=93125"},{"taxonomy":"sector","embeddable":true,"href":"https:\/\/livingstonepartners.com\/fr\/wp-json\/wp\/v2\/sector?post=93125"},{"taxonomy":"service","embeddable":true,"href":"https:\/\/livingstonepartners.com\/fr\/wp-json\/wp\/v2\/service?post=93125"},{"taxonomy":"transaction-type","embeddable":true,"href":"https:\/\/livingstonepartners.com\/fr\/wp-json\/wp\/v2\/transaction-type?post=93125"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}